News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
OncoArendi Therapeutics has received the final report from the phase Ib clinical trial of innovative drug candidate OATD-01
10 September 2020
Dr. Zbigniew Zasłona joins OncoArendi Therapeutics as the new Director of the Biology Department. Dr Paweł Dobrzański, the current head of the Biology Department, will still be engaged in collaboration with OncoArendi as Senior Scientific Advisor on the company’s Scientific Advisory Board.
9 September 2020
A new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship
13 May 2020
OncoArendi Therapeutics has completed a Phase Ib clinical trial with an innovative small molecule experimental drug – OATD-01. Further analyses of the data from the study will lead to the final report and advancing to phase II clinical trials in patients
20 April 2020
Drug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)
24 March 2020